Free Trial
NASDAQ:BIAF

bioAffinity Technologies (BIAF) Stock Price, News & Analysis

bioAffinity Technologies logo
$0.26 -0.09 (-25.51%)
Closing price 04:00 PM Eastern
Extended Trading
$0.26 0.00 (-0.77%)
As of 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About bioAffinity Technologies Stock (NASDAQ:BIAF)

Key Stats

Today's Range
$0.25
$0.31
50-Day Range
$0.23
$0.37
52-Week Range
$0.16
$2.26
Volume
13.65 million shs
Average Volume
7.32 million shs
Market Capitalization
$7.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

bioAffinity Technologies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
8th Percentile Overall Score

BIAF MarketRank™: 

bioAffinity Technologies scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of bioAffinity Technologies is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of bioAffinity Technologies is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    bioAffinity Technologies has a P/B Ratio of 1.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about bioAffinity Technologies' valuation and earnings.
  • Percentage of Shares Shorted

    4.99% of the float of bioAffinity Technologies has been sold short.
  • Short Interest Ratio / Days to Cover

    bioAffinity Technologies has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in bioAffinity Technologies has recently increased by 8.53%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    bioAffinity Technologies does not currently pay a dividend.

  • Dividend Growth

    bioAffinity Technologies does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.99% of the float of bioAffinity Technologies has been sold short.
  • Short Interest Ratio / Days to Cover

    bioAffinity Technologies has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in bioAffinity Technologies has recently increased by 8.53%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    bioAffinity Technologies has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for bioAffinity Technologies this week, compared to 1 article on an average week.
  • Search Interest

    7 people have searched for BIAF on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, bioAffinity Technologies insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.93% of the stock of bioAffinity Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 1.64% of the stock of bioAffinity Technologies is held by institutions.

  • Read more about bioAffinity Technologies' insider trading history.
Receive BIAF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bioAffinity Technologies and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BIAF Stock News Headlines

$3,600 gold is nice ... but here’s what most gold bugs are missing
Gold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold stocks — in past bull markets, these plays delivered gains as high as 5,000% to 9,800%, and Sean has now identified five companies he believes could see explosive moves in the early stages of what may be the biggest gold rally yet.tc pixel
bioAffinity Technologies Appoints New Board Members
See More Headlines

BIAF Stock Analysis - Frequently Asked Questions

bioAffinity Technologies' stock was trading at $0.91 at the start of the year. Since then, BIAF shares have decreased by 70.9% and is now trading at $0.2650.

bioAffinity Technologies, Inc. (NASDAQ:BIAF) posted its quarterly earnings results on Thursday, August, 14th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by $0.03. The business had revenue of $1.27 million for the quarter, compared to the consensus estimate of $1.51 million. bioAffinity Technologies had a negative trailing twelve-month return on equity of 845.68% and a negative net margin of 152.16%.

bioAffinity Technologies (BIAF) raised $8 million in an initial public offering on Thursday, September 1st 2022. The company issued 1,300,000 shares at $6.00-$6.25 per share. WallachBeth Capital acted as the underwriter for the IPO and Craft Capital Management was co-manager.

Shares of BIAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that bioAffinity Technologies investors own include Lowe's Companies (LOW), Meta Platforms (META), Costco Wholesale (COST), Intel (INTC), AIM ImmunoTech (AIM), Alnylam Pharmaceuticals (ALNY) and Ambrx Biopharma (AMAM).

Company Calendar

Last Earnings
8/14/2025
Today
9/16/2025
Next Earnings (Estimated)
11/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Business Services
Current Symbol
NASDAQ:BIAF
CIK
1712762
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.70)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$9.04 million
Net Margins
-152.16%
Pretax Margin
-151.64%
Return on Equity
-845.68%
Return on Assets
-181.92%

Debt

Debt-to-Equity Ratio
0.27
Current Ratio
0.64
Quick Ratio
0.63

Sales & Book Value

Annual Sales
$9.36 million
Price / Sales
0.83
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.17 per share
Price / Book
1.61

Miscellaneous

Outstanding Shares
28,470,000
Free Float
23,649,000
Market Cap
$7.80 million
Optionable
Not Optionable
Beta
2.53

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:BIAF) was last updated on 9/16/2025 by MarketBeat.com Staff
From Our Partners